# Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

> **NCT01965106** · PHASE2 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Glaucoma, Angle-closure, Primary, Acute

## Interventions

- **DRUG:** QPI-1007 Injection
- **DRUG:** (including placebo)

## Key facts

- **NCT ID:** NCT01965106
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965106, "Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01965106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*